mAbxience SA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:mAbxience SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11243
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mabxience SA (mAbxience), a subsidiary of Chemo Espana SA, is a biotechnology company that research, develops and manufactures biosimilar monoclonal antibodies. The company develops biosimilars, which are used for the treatment and prevention of various diseases in onclology such as breast cancer, colon cancer, some types of lymphoma and autoimmune diseases. It carries out clinical follow-up through pharmacovigilance programs that allow the detection of delayed toxicities. mAbxience also offers technical transfer support and regulatory services. The company operates through its offices in Switzerland, Spain, Argentina and Uruguay. mAbxience is headquartered in Lugano, Switzerland.

mAbxience SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
mAbxience SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
mAbxience SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Amneal Pharma Enters into Licensing Agreement with mAbxience 10
mAbxience Partners with World Health Organization and Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health 11
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 12
Licensing Agreements 13
Libbs Farma Enters Into Licensing Agreement With mAbxience For Biosimilar Monoclonal Antibodies 13
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 14
Acquisition 15
mAbxience Acquires GH Genhelix for USD13.5 Million 15
mAbxience SA – Key Competitors 16
mAbxience SA – Key Employees 17
mAbxience SA – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
mAbxience SA, Pharmaceuticals & Healthcare, Key Facts 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Deals By Therapy Area, 2012 to YTD 2018 8
mAbxience SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Amneal Pharma Enters into Licensing Agreement with mAbxience 10
mAbxience Partners with World Health Organization and Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health 11
EPIRUS Biopharma Enters into Distribution Agreement with mAbxience 12
Libbs Farma Enters Into Licensing Agreement With mAbxience For Biosimilar Monoclonal Antibodies 13
Stada Arzneimittel to Enter into Licensing Agreement with mAbxience 14
mAbxience Acquires GH Genhelix for USD13.5 Million 15
mAbxience SA, Key Competitors 16
mAbxience SA, Key Employees 17
mAbxience SA, Other Locations 18
mAbxience SA, Subsidiaries 18

List of Figures
mAbxience SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
mAbxience SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
mAbxience SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[mAbxience SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Reliance Industries Limited:企業の戦略・SWOT・財務情報
    Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Reliance Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Herti AD:企業の戦略・SWOT・財務情報
    Herti AD - Strategy, SWOT and Corporate Finance Report Summary Herti AD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Bord na Mona Plc:企業の戦略的SWOT分析
    Bord na Mona Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Australian Gas Networks Ltd:電力:M&Aディール及び事業提携情報
    Summary Australian Gas Networks Ltd (Australian Gas Networks), formerly Envestra Ltd is an oil and gas company that distributes and transports natural gas. The company's services include managing the haulage of gas through each network, operation and maintenance of gas network, design an constructio …
  • Meijer Inc:戦略・SWOT・企業財務分析
    Meijer Inc - Strategy, SWOT and Corporate Finance Report Summary Meijer Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Innovation Pharmaceuticals Inc (IPIX)-製薬・医療分野:企業M&A・提携分析
    Summary Innovation Pharmaceuticals Inc (Innovation Pharmaceuticals), formerly Cellceutix Corp is a biopharmaceutical company that offers discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications. The company offers kevetrin for t …
  • Cordis Corp-医療機器分野:企業M&A・提携分析
    Summary Cordis Corporation (Cordis), a subsidiary of a Cardinal Health Inc., develops and manufactures interventional vascular products in the area of cardiology as well as for use in endovascular surgery. The company’s cardiology portfolio comprises sheaths, diagnostic guidewires, diagnostic cathet …
  • Specialist Computer Centres Plc:企業の戦略・SWOT・財務情報
    Specialist Computer Centres Plc - Strategy, SWOT and Corporate Finance Report Summary Specialist Computer Centres Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Cairn Energy Plc (CNE):石油・ガス:M&Aディール及び事業提携情報
    Summary Cairn Energy Plc (Cairn Energy) is an independent oil and gas exploration and production company. It has a diversified portfolio of assets across core areas of the mature basins of the UK and Norwegian North Sea, emerging basins in Senegal, Barents Sea and Mexico and frontier basins along th …
  • Welspun India Ltd (WELSPUNIND):企業の財務・戦略的SWOT分析
    Welspun India Ltd (WELSPUNIND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Nippon Chemiphar Co Ltd (4539):企業の財務・戦略的SWOT分析
    Summary Nippon Chemiphar Co Ltd (Nippon Chemiphar) is a provider of pharmaceutical drugs and health-related services. The company manufactures, supplies, imports and exports ethical pharmaceuticals and diagnostic agents. Nippon Chemiphar offers diagnostic products, such as IgE NC, a diagnostic kit t …
  • Northern Biologics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Northern Biologics Inc (Northern Biologics) is a biotechnology company, which develops antibody-based- immuno-oncology medicines for treating cancers. Its pipeline product portfolio includes MSC-1, a first-in-class humanized antibody targeting leukemia inhibitory factor (LIF), a major immuno …
  • TDC AS (TDC):企業の財務・戦略的SWOT分析
    TDC AS (TDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Orpak Systems Limited:企業の戦略的SWOT分析
    Orpak Systems Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Linde Malaysia Sdn Bhd:企業の戦略的SWOT分析
    Linde Malaysia Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Iridex Corp (IRIX)-医療機器分野:企業M&A・提携分析
    Summary Iridex Corp (IRIDEX) is a medical device company that manufactures and distributes laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology and otolaryngology market. The company provides products such as lasers, laser delivery devices, glaucoma devi …
  • Toyobo Co Ltd (3101):企業の財務・戦略的SWOT分析
    Toyobo Co Ltd (3101) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • National Bank Of Kuwait Sak
    National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report Summary National Bank Of Kuwait Sak - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM …
  • Oil India Limited:企業の戦略・SWOT・財務分析
    Oil India Limited - Strategy, SWOT and Corporate Finance Report Summary Oil India Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆